| Empire Vision Centers | |
|
125 Shop City Plaza, Syracuse, NY 13206-1943 | |
| (315) 463-7700 | |
| (315) 463-2938 |
| Full Name | Empire Vision Centers |
|---|---|
| Type | Facility |
| Speciality | Technician/technologist |
| Location | 125 Shop City Plaza, Syracuse, New York |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093778763 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Secondary |
| 156F00000X | Technician/technologist | (* (Not Available)) | Primary |
| 332H00000X | Eyewear Supplier | (* (Not Available)) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Empire Vision Centers 2921 Erie Blvd East, Syracuse, NY 13224-1430 Ph: (315) 446-3145 | Empire Vision Centers 125 Shop City Plaza, Syracuse, NY 13206-1943 Ph: (315) 463-7700 |
News Archive
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
Scientists have uncovered a new region in the genome that is responsible for the body's ability to regulate bad cholesterol which is linked to heart attack and stroke.
Karen Davis will retire as president of the Commonwealth Fund, a health care research foundation, at the end of 2012. The foundation, based in New York, has hired an executive search firm to find Davis' successor. In a news release announcing her retirement, Davis said she would spend her final year helping with the leadership transition and "pursuing opportunities for contributing toward the work that is so important to ensuring that every American receives the best possible care and the opportunity to lead healthy, productive lives."
AngioDynamics announced today the launch of a new access kit allowing fewer procedure steps and faster procedure time for physicians using the VenaCure EVLT system's NeverTouch® gold-tip laser fiber to treat varicose veins.
OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, today announced positive interim analysis of data from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck (HNSCC) treated with OMS ElectroChemotherapy in Europe.
› Verified 1 days ago